Tamayo Louis Edward
Chief Financial Officer
Tamayo Louis Edward has filed 4 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Aug 19, 2026.
On the most recent filing, Tamayo Louis Edward is listed as Chief Financial Officer at Lexeo Therapeutics, Inc. Inside the rolling window, Tamayo Louis Edward reported no open-market purchases and 2 open-market sales totaling $41K in LXEO. The largest disclosed transaction in the window is a sale of 4,641 LXEO shares on Jul 1, 2026, worth $21K.
Companies traded
Other insiders at LXEO
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$41K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Tamayo Louis Edward made?
Tamayo Louis Edward has filed 4 SEC Form 4 filings (5 transaction rows) across 1 company since 2025.
Which companies does Tamayo Louis Edward trade?
Tamayo Louis Edward has filed SEC Form 4 disclosures for 1 company, including LXEO.
When was Tamayo Louis Edward's most recent SEC Form 4 filing?
Tamayo Louis Edward's most recent SEC Form 4 filing on Tracefour is dated Aug 19, 2026.
What is Tamayo Louis Edward's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Tamayo Louis Edward is listed as Chief Financial Officer.
What is Tamayo Louis Edward's total buy and sell value in the current window?
Inside the rolling retention window, Tamayo Louis Edward bought $0 and sold $41K based on SEC Form 4 filings.
What was Tamayo Louis Edward's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 4,641 LXEO shares on 2026-07-01, worth $21K, per SEC Form 4 filings.